NCT06989359View on ClinicalTrials.gov

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
IgANC3GComplement-mediated Kidney Disease
Interventions
DRUG

ADX-038

siRNA duplex oligonucleotide

Sponsors
All Listed Sponsors
lead

ADARx Pharmaceuticals, Inc.

INDUSTRY